Baxter buys Oncaspar portfolio for $900M; Lilly readies $18M milestone for Hutchison;

@FierceBiotech: China's BeiGene banks $97M to get its cancer drugs into the clinic. Article | Follow @FierceBiotech

@JohnCFierce: No, the IPO flood won't float all boats. Gelesis scraps plans, for now, for a $52M IPO. More | Follow @JohnCFierce

> Baxter ($BAX) is acquiring the Oncaspar (pegaspargase) product portfolio from Sigma-Tau Finanziaria S.p.A. for $900 million. News

> Eli Lilly ($LLY) is set to make an $18 million milestone payment to Hutchison MediPharma, majority owned by Hutchison China MediTech, or Chi-Med, in the second quarter of 2015 after a positive first proof-of-concept study result for fruquintinib, a candidate for treatment of patients with metastatic colorectal cancer in China. Story

> AstraZeneca ($AZN) struck two deals to expand its R&D reach, teaming up with Abbott Laboratories ($ABT) to develop an asthma diagnostic and tapping the Montreal Heart Institute to examine more than 80,000 patients in hopes of better understanding the root causes of cardiovascular diseases. Item

> Soligenix ($SNGX) has teamed up with Emergent BioSolutions ($EBS) to develop a vaccine for ricin poisoning. More

Medical Device News

@FierceMedDev: FDA approves Roche's cancer diagnostic as a guide to use of Amgen, Lilly meds. FierceDiagnostics story | Follow @FierceMedDev

@VarunSaxena2: Lilly hopes new drug delivery R&D center will prove useful in osteoporosis, diabetes arenas. FierceDrugDelivery article | Follow @VarunSaxena2

@EmilyWFierce: ICYMI from FiercePharma: Biogen's hot MS meds could push Pfizer off its CNS throne. Report | Follow @EmilyWFierce

> Glaucoma micro stent player Glaukos files to raise up to $86M in an IPO. Story

> Seattle hospital sues Olympus over duodenoscope devices tied to superbug outbreak. Article

Pharma News

@FiercePharma: Phibro records strong sales growth despite industry shift from antibiotics. FierceAnimalHealth story | Follow @FiercePharma

@EricPFierce: Alexion expanding in Ireland. Will spend $506M on its first biologics plant outside of U.S. News from FiercePharmaManufacturing | Follow @EricPFierce

@CarlyHFierce: Endo plots a relaunch of Auxilium's ED med, complete with new salesforce and DTC. FiercePharmaMarketing report | Follow @CarlyHFierce

> Vertex eyes big revenue boost with FDA panel backing for Orkambi. More

> Senator asks VA to yank patent on Gilead's Sovaldi to crush its price. Report

Pharma Marketing News

> Wrongfully fired rep needs a real job offer, judge tells Bayer. And fork over that back pay, stat. More

> Want to know a secret? Pharma's patient services are going to waste. News

> Can pharma + tech wearables be a match made in patient heaven? Report

> Lucky 7 diabetes meds to join blockbuster club by 2020. Story

> Endo plots a relaunch of Auxilium's ED med, complete with new salesforce and DTC. More

Biotech Research News

> Moderna tops CNBC's list of most disruptive new technologies. Item

> VCU scientist preps gene therapy/drug combo for PhI prostate cancer study. Story

> Garvan team spotlights role of rogue cells in autoimmune diseases. Article

> Swift setback: A preclinical success in hep B is followed by safety woes. News

> Biopharma companies jump into the big data stampede for genetic triggers of disease. Report

Diagnostics News

> Soon-Shiong reels in $100M for cancer genomics unit. Item

> FDA approves Roche's cancer diagnostic as a guide to use of Amgen, Lilly meds. Story

> Navidea scores $60M loan to broaden reach for Lymphoseek. Article

> HTG Molecular Diagnostics unveils $50M IPO for genomic profiling technology. More

> Adaptive Biotechnologies reels in $195M for immunosequencing tech. News

Suggested Articles

Akero's FGF21 analog beat placebo at reducing liver fat in patients with nonalcoholic steatohepatitis (NASH).

Amgen has become the latest biopharma to try to figure out the hit it may take to its pipeline timings amid the COVID-19 pandemic.

The database was locked at the end of February but will only be unblinded after the FDA has provided feedback.